Get notified when SDGR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Standing Risk Factors

  • Material Weakness (unchanged) — The company continues to disclose a previously identified and remediated material weakness from 2022, with no new weakness reported.
NASDAQ: SDGR Schrodinger, Inc. 10-Q

Schrodinger swings to Q2 profit on $6.0M Ajax payout; software revenue to decline near-term

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read

Key Changes

  • high

    Q2 net income of $6.0M ($0.08 diluted EPS) driven by a one-time $57.2M cash payment from Lilly's acquisition of Ajax Therapeutics.

    MD&A: Ajax payout verify on EDGAR →
  • high

    Software revenue expected to decline near-term as the company accelerates transition from on-premise to hosted contracts.

    Risk Factors: Revenue transition verify on EDGAR →
  • high

    Restructuring savings estimate raised from $30M to approximately $70M annually, reflecting broader cost reductions.

    MD&A: Restructuring verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.

Partner

Trade SDGR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify